# Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)

> **NCT00111423** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 216 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Pegsunercept (PEG sTNF-RI)

## Key facts

- **NCT ID:** NCT00111423
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 216 (—)
- **Last updated:** 2009-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111423, "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00111423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*